The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...